Skip to main content
Lincoln Pharmaceuticals ltd. logo

Lincoln Pharmaceuticals ltd. — Investor Relations & Filings

Ticker · LINCOLN ISIN · INE405C01035 LEI · 3358004B6OBJNW8RTT10 BSE.NS Manufacturing
Open in API
Filings indexed 446 across all filing types
Latest filing 2026-02-04 Regulatory Filings
Country IN India
Listing BSE.NS LINCOLN

About Lincoln Pharmaceuticals ltd.

https://www.lincolnpharma.com/

Lincoln Pharmaceuticals Ltd. focuses on the development, manufacturing, and marketing of a diverse range of therapeutic formulations. The organization operates advanced manufacturing facilities certified by international standards, including WHO-GMP. Its portfolio spans multiple areas such as anti-infectives, cardiovascular, gastrointestinal, respiratory, and pain management. The company is recognized for its research and development initiatives, particularly in Novel Drug Delivery Systems (NDDS). Key offerings include specialized treatments for tinnitus and a wide array of formulations in dosage forms like tablets, capsules, liquid orals, and injectables. It maintains a significant global footprint, supplying products to numerous international markets across Africa, Southeast Asia, and Latin America, supported by a robust distribution network for its extensive healthcare catalog.

Recent filings

Filing Released Lang Actions
Board Meeting — Board Meeting Intimation
Regulatory Filings
2026-02-04 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) informing them about an upcoming board meeting scheduled for February 12, 2026. The purpose of the meeting is to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025. The letter also mentions the closure of the trading window as per SEBI regulations. The document does not contain the financial results themselves, nor detailed financial data or analysis. It is a notification about the board meeting and the expected approval of interim financial results. The document length is 2585 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about a board meeting and upcoming financial results, not the financial report itself or a detailed management discussion.
2026-02-04 English
Credit Rating
Audit Report / Information Classification · 95% confidence The document is a detailed credit rating rationale report issued by CRISIL Limited for Lincoln Pharmaceuticals Limited dated January 9, 2026. It contains extensive financial data, analysis of the company's business risk profile, financial risk profile, liquidity, outlook, and rating sensitivity factors. The document includes key financial indicators, details of bank facilities, and annexures related to the rating. It is not a brief announcement or a certification letter but a comprehensive standalone report on the credit rating reaffirmation. The content aligns with the characteristics of an Audit Report / Information (AR) as it provides audit-related credit rating information and financial analysis without being a full annual report or earnings release. Therefore, the appropriate classification is AR with high confidence.
2026-01-10 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate submitted under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming dematerialisation activities for the quarter ended December 31, 2025. It is addressed to stock exchanges and signed by the company secretary and the registrar & share transfer agent. The content is a compliance certificate rather than a financial report or announcement of financial results. The document length is under 5,000 characters and primarily serves as a regulatory compliance filing. It does not contain financial statements, management discussion, or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS) as a compliance certificate submission.
2026-01-06 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) informing about the closure of the trading window pursuant to SEBI regulations related to insider trading. It specifies the trading window closure period around the announcement of quarterly financial results for the quarter ended December 31, 2025. The document is a formal notification about trading restrictions and does not contain any financial data, results, or detailed report content. It is not an earnings release or financial report but an announcement related to compliance and trading restrictions. Given the nature and length (2662 characters), it is not a full report but a regulatory announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2025-12-24 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) regarding the publication of un-audited financial results for the quarter and half year ended September 30, 2025. It references Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates disclosure of financial results. The document includes a newspaper advertisement of these un-audited financial results and mentions that the full financial results and auditor's limited review report are available on the company's website and stock exchange websites. The document itself is not the full financial report but an announcement of the publication of the un-audited financial results. It is also about un-audited quarterly and half-year results, which corresponds to an Interim / Quarterly Report. However, since the document is primarily a newspaper advertisement and notification of the results publication, and not the full report containing substantive financial data and analysis, it fits best as a Regulatory Filing (RNS) under the SEBI regulations. The document length is 15,000 characters, but the content is an announcement and advertisement of the un-audited financial results, not the full report itself.
2025-11-14 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.